Experience of immune-related adverse events associated with anti-CTLA-4 and anti-PD1 checkpoint inhibitors in a single center

被引：0
|
作者：
Rapoport, B. L. [1 ]
Smit, T. [1 ]
Van Eeden, R. I. [1 ]
机构：
[1] Med Oncol Ctr Rosebank, Med Oncol, Johannesburg, South Africa
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
24P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy of anti-CTLA-4 after progression on anti-PD1 therapy in advanced melanoma
    Aya Moreno, F.
    Fernandez-Martinez, A.
    Gaba, L.
    Victoria, I.
    Arance Fernandez, A. M.
    ANNALS OF ONCOLOGY, 2015, 26 : 6 - 6
  • [42] Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
    Cortellini, Alessio
    Chiari, Rita
    Ricciuti, Biagio
    Metro, Giulio
    Perrone, Fabiana
    Tiseo, Marcello
    Bersanelli, Melissa
    Bordi, Paola
    Santini, Daniele
    Giusti, Raffaele
    Grassadonia, Antonino
    Di Marino, Pietro
    Tinari, Nicola
    De Tursi, Michele
    Zoratto, Federica
    Veltri, Enzo
    Malorgio, Francesco
    Garufi, Carlo
    Russano, Marco
    Anesi, Cecilia
    Zeppola, Tea
    Filetti, Marco
    Marchetti, Paolo
    Berardi, Rossana
    Rinaldi, Silvia
    Tudini, Marianna
    Silva, Rosa Rita
    Pireddu, Annagrazia
    Atzori, Francesco
    Iacono, Daniela
    Migliorino, Maria Rita
    Porzio, Gampiero
    Cannita, Katia
    Ficorella, Corrado
    Buti, Sebastiano
    CLINICAL LUNG CANCER, 2019, 20 (04) : 237 - +
  • [43] Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
    Yeonghee Eun
    In Young Kim
    Jong-Mu Sun
    Jeeyun Lee
    Hoon-Suk Cha
    Eun-Mi Koh
    Hyungjin Kim
    Jaejoon Lee
    Scientific Reports, 9
  • [44] Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
    Eun, Yeonghee
    Kim, In Young
    Sun, Jong-Mu
    Lee, Jeeyun
    Cha, Hoon-Suk
    Koh, Eun-Mi
    Kim, Hyungjin
    Lee, Jaejoon
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [45] Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
    Rose, April A. N.
    Armstrong, Susan M.
    Hogg, David
    Butler, Marcus O.
    Saibil, Samuel D.
    Arteaga, Diana P.
    Muniz, Thiago Pimentel
    Kelly, Deirdre
    Ghazarian, Danny
    King, Ian
    Kamil, Zaid Saeed
    Ross, Kendra
    Spreafico, Anna
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
  • [46] Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials
    Zhang, Leyin
    Sun, Leitao
    Zhou, Yiwen
    Yu, Jieru
    Lin, Yingying
    Wasan, Harpreet S.
    Shen, Minhe
    Ruan, Shanming
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry
    Sun, Michel M.
    Kelly, Scott P.
    Mylavarapu, Apoorva L.
    Holland, Gary N.
    Coleman, Anne L.
    Yu, Fei
    Hsu, Stephen
    Lum, Flora
    Gordon, Lynn K.
    OPHTHALMOLOGY, 2021, 128 (06) : 910 - 919
  • [48] Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
    Willsmore, Zena N.
    Coumbe, Ben G. T.
    Crescioli, Silvia
    Reci, Sara
    Gupta, Ayushi
    Harris, Robert J.
    Chenoweth, Alicia
    Chauhan, Jitesh
    Bax, Heather J.
    McCraw, Alexa
    Cheung, Anthony
    Osborn, Gabriel
    Hoffmann, Ricarda M.
    Nakamura, Mano
    Laddach, Roman
    Geh, Jenny L. C.
    MacKenzie-Ross, Alastair
    Healy, Ciaran
    Tsoka, Sophia
    Spicer, James F.
    Josephs, Debra H.
    Papa, Sophie
    Lacy, Katie E.
    Karagiannis, Sophia N.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 (03) : 544 - 556
  • [49] Anti-PD-1 antibodies: immune-related adverse events and efficacy
    Reactions Weekly, 2019, 1739 (1) : 6 - 6
  • [50] Immune-related adverse events with resumed anti-PD-1 therapy
    Reactions Weekly, 2017, 1676 (1) : 4 - 4
12345